Recombinant Mouse TNFSF7/CD70 Protein (Fc Tag)(Active)

Cd27l, CD27LG, Tnfsf7

1.Measured by its binding ability in a functional ELISA.2.Immobilized mouse CD27-His at 10ug/mL (100uL/well) can bind mouse CD70 , the EC50 of mouse CD70 is 10-50 ng/mL.

Gln47-Pro195

NP_035747.1

> (12.5+86.3) % as determined by SDS-PAGE

Lyophilized proteins are stable for up to 12 months when stored at -20 to -80CC. Reconstituted protein solution can be stored at 4-8C for 2-7 days. Aliquots of reconstituted samples are stable at < -20C for 3 months.

Lyophilized from sterile PBS, pH 7.4

CD70, a member of the tumor necrosis factor superfamily, is restricted to activated T-and B-lymphocytes and mature dendritic cells. Binding of CD70 to its receptor, CD27, is important in priming, effector functions, differentiation and memory formation of T-cells as well as plasma and memory B-cell generation. Tight control of CD70 expression is required to prevent lethal immunodeficiency. By selective transcription, CD70 is largely confined to activated lymphocytes and dendritic cells (DC). As a type II transmembrane receptor, CD70 is normally expressed on a subset of B, T and NK cells, where it plays a costimulatory role in immune cell activation. Immunohistochemical analysis of CD70 expression in multiple carcinoma types. The restricted expression pattern of CD70 in normal tissues and its widespread expression in various malignancies makes it an attractive target for antibody-based therapeutics. Investigations to exploit CD70 as a cancer target have lead to the identification of potential antibody-based clinical candidates.Immune CheckpointImmune Checkpoint ProteinsImmune Checkpoint Targets      Co-stimulatory Immune Checkpoint Targets Immunotherapy      Cancer Immunotherapy      Targeted Therapy